Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/1999
10/27/1999EP0951542A2 Secreted proteins and polynucleotides encoding them
10/27/1999EP0951540A2 Antisense nucleic acids and hammerhead ribozymes
10/27/1999EP0951537A1 Recombinant collagen and derived proteins produced by plants, methods for obtaining them and uses
10/27/1999EP0951536A1 Synthetic antisense oligodeoxynucleotides and pharmaceutical compositions containing them
10/27/1999EP0951532A1 Bivalent agonists for g-protein coupled receptors
10/27/1999EP0951481A1 Use of substances with immunomodulating activity for the treatment of amyotrophic lateral sclerosis
10/27/1999EP0951480A1 Method and novel compounds for use therein
10/27/1999EP0951478A1 Polysaccharide-peptide derivatives
10/27/1999EP0951476A2 Complement inhibitor
10/27/1999EP0951474A1 Novel cyclosporin derivatives, method of preparation and pharmaceutical compositions containing them
10/27/1999EP0951473A1 Cyclosporin derivative, its preparation and pharmaceutical compositions containing same
10/27/1999EP0951472A1 Peptide compositions with growth factor-like activity
10/27/1999EP0951471A1 Cycloalkyl inhibitors of protein farnesyltransferase
10/27/1999EP0951469A1 Novel compounds
10/27/1999EP0951466A2 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
10/27/1999EP0951300A1 Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
10/27/1999EP0951298A1 Diagnosis and treatment of pathological pregnancies
10/27/1999EP0951295A1 Methods and compositions useful for inhibition of angiogenesis
10/27/1999EP0951294A1 Wound healing formulations containing human plasma fibronectin
10/27/1999EP0951292A1 Methods for treating an ischemic disorder and improving stroke outcome
10/27/1999EP0951286A2 Method of treating prostatic diseases using delayed and/or sustained release vitamin d formulations
10/27/1999EP0951283A1 Novel arachidonic acid metabolite, 16-hete
10/27/1999EP0951272A1 An oral care product comprising a mutan binding domain
10/27/1999EP0759938A4 Neurogenic differentiation (neurod) genes and proteins
10/27/1999EP0590082B1 Antisense oligonucleotide inhibition of the ras gene
10/27/1999EP0533862B1 Recombinant human factor viii derivatives
10/27/1999EP0167575B2 Cardiodilatine, a peptide hormone and production process thereof
10/27/1999CN1233291A Method for recombinant adeno-associated virus-directed gene therapy
10/27/1999CN1233289A TNF-Beta-like protein for treating prostate cancer, and related nucleic acid molecules, pharmaceutical compositions and methods
10/27/1999CN1233258A Method for producing an IgM preparation for intravenous administration
10/27/1999CN1233257A Polypeptide transition metal salts and method of enhancing anti-HIV activity of polypeptide
10/27/1999CN1233256A Dipeptide benzamidine as a kininogenase inhibitor
10/27/1999CN1233237A Heteroaryl succinamides and their use as metalloproteinase inhibitors
10/27/1999CN1233189A Treatment of asthma with TNFR-Ig
10/27/1999CN1233187A HIVp-17 peptide fragment, compositions containing and methods for producing and using same
10/27/1999CN1233186A A method for the treatment of streptococcus pneumoniae infection
10/27/1999CN1233185A Nucleosome-based anti-tumor compositions
10/27/1999CN1233171A Inhibition of nuclear transcription factor NF-'kappa' B by caffeic acid phenethyl ester (CAPE), derivatives of CAPE, capsaicin (8-methyl-N-vanillyl-6-nonenamide) and resiniferatoxin
10/27/1999CA2269995A1 Process for the preparation of pharmaceutical compositions possessing neurogenic or non-neurogenic anti-inflammatory as well as analgetic effects
10/26/1999US5973136 Inverted chimeric oligonucleotides
10/26/1999US5973134 Rat CNP complementary DNA and precursor protein
10/26/1999US5973132 Expression of dna coding for house dust mite allergens.
10/26/1999US5973131 Diagnosis of systemic infections of penicillium marneffei by detecting the presence of the specific antibodies as well as the pmap1 protein antigen.
10/26/1999US5973130 Antiproliferative/antiarthric/antidiabetic/antiallergen andantiinflammatory agents; diagnosis and treatment of acquired immuno deficiency syndrome, crohn's/addison's diseases, ulcers, osteoporsis
10/26/1999US5973122 Serum immunoregulatory polypeptides and uses therefor
10/26/1999US5973121 The ingestion of peanuts is a common cause of food hypersensitivity reactions.
10/26/1999US5973120 Bovine and human polynucleotides and peptides expressed by such polynucleotides which are useful in detecting goodpasture antibodies and treating goodpasture syndrome.
10/26/1999US5973117 Isolated and purified receptor protein endogenous to rt, bovine, or human, capable of binding a pituitary adneylate cyclase activating polypeptide (pacap) or salt, and amino acid sequences encoding it; diagnostic, e.g. of neuropathy
10/26/1999US5973114 Isolated purified growth hormone releasing hormone (ghrh) receptor of given molecular weight; made by solubilization of ghrh-r/ghrh complexes and extraction of bound ghrh using mild detergent followed by affinity chromatography
10/26/1999US5973112 Comprising tripeptide unit of the formula (xaaflpgly)n, where xaa is any amino acid, flp is 4(r)-fluoro-l-proline, and n is at least 7; increased stability; stronger triple helix than native collagen; for use such as in artificial skin
10/26/1999US5973111 Novel compounds that are capable of binding to the active site of interleukin-1b-converting enzyme (ice) and inhibiting activity of that enzyme; administering to treat inflammatory, autoimmune, and neurodegenerative diseases
10/26/1999US5973110 Inhibiting the bio-activity of enzymes.
10/26/1999US5973011 Administration of 6 mg/kg/day of an organic nitrate to an individual to maintain or improve endothelial function
10/26/1999US5973009 Antioxidant and cytoprotecting activity
10/26/1999US5972990 Administering angiotensin ii inhibitors, such as losartan to patients who are otherwise free of indications for angiotensin ii inhibition treatment and have left ventricular ejection fraction of 40% or less
10/26/1999US5972989 Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
10/26/1999US5972940 Arginine analogues having nitric oxide synthase inhibitor activity
10/26/1999US5972924 Administering cyclosporin a to a human whose blood-brain barrier has been opened, or where cyclosporin a is able to cross the blood brain barrier
10/26/1999US5972923 Methods and compositions to enhance the cytoprotective effects of polycyclic phenolic compounds through the synergistic interaction with anti-oxidants
10/26/1999US5972902 DNA encoding human IL-6 receptor antagonist and protein encoded thereby
10/26/1999US5972900 Conjugating target binding moiety consisting of an antibody or fragment which binds to secretory component of polymeric immunoglobulin receptor on surface of epithelium cell, nucleic acid binder, expression vector, compacting, administering
10/26/1999US5972899 Apoptosis induced by Shigella IpaB
10/26/1999US5972897 Acylated enol derivatives as prodrugs of elastase inhibitors
10/26/1999US5972896 Antiangiogenic peptides and methods for inhibiting angiogenesis
10/26/1999US5972895 Peptide consisting of the formula a1-d2methyltrp-ala-trp-dphe-lys wherein a1 is glutamine (gln) or glutamic acid (glu), and organic or inorganic pharmaceutically acceptable salts thereof
10/26/1999US5972894 Peptides having potassium channel opener activity
10/26/1999US5972893 Method of treating hyperprolactinemia and prolactinomas
10/26/1999US5972892 For reducing or eliminating the skin irritant side-effect of a therapeutic composition; a stabilizer for desensitization
10/26/1999US5972891 A mixture comprising an active nonapeptide or decapeptide and a biodegradable polymer having a terminal carboxyl group, showing constant release of the peptide over a long time
10/26/1999US5972890 Polypeptide with label; diagnosis
10/26/1999US5972888 Lowering the production or release of neuropeptide y which comprises administering to a mammal in need thereof an effective amount of an isolated naturally occurring obesity protein, or a pharmaceutically acceptable salt thereof
10/26/1999US5972887 Increasing intestinal mucosal substrate absorptive function and intestinal tissue mass of small intestine beyond the normal adaptive response in a patient by administering a low dosage of hepatocyte growth factor intraluminally
10/26/1999US5972886 Amino acid sequences, a gene coding for stimulating cell differentiation of megakaryocytes; increasing blood platelet cells
10/26/1999US5972885 Method for treatment of hemophilia by extravascular administration of factor VIII deletion derivatives
10/26/1999US5972884 Morphogen treatment of gastrointestinal ulcers
10/26/1999US5972883 Vasoactive intestinal peptide; a polypeptide
10/26/1999US5972882 Treatment of polycystic kidney disease using vasopressin V2 receptor antagonists
10/26/1999US5972881 Treating NIDDM with RXR agonists
10/26/1999US5972880 Method of treatment of osteoarthritis with interleuken-1 receptor antagonist
10/26/1999US5972879 Inhibiting agent against the proliferation of tumor cells
10/26/1999US5972704 HIV nef targeted ribozymes
10/26/1999US5972702 There also exists a need to identify the gene(s) responsible for osteopetrosis and to provide a genetic therapy for treating osteopetrosis. an object of the invention is to provide compounds that desirably influence the bone remodeling
10/26/1999US5972701 Nucleotide sequence of ribo- or deoxyribonucleotides which may have modified sugars, bases, or phosphates; for hybridization and cleavage of rna targets; treatment of disease
10/26/1999US5972699 Method and reagent for inhibiting herpes simplex virus replication
10/26/1999US5972698 Tryptase is expressed virtually exclusively by mast cells.
10/26/1999US5972697 NIMA interacting proteins
10/26/1999US5972688 HTm4 methods of treatment and assays, agonists and antagonists
10/26/1999US5972680 An aminopeptidase which is involved in insulin regulation.
10/26/1999US5972676 Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders
10/26/1999US5972674 May be used, for example, to identify antibodies and other agents that inhibit or activate signal transduction via the nf-.kappa.b cascade.
10/26/1999US5972666 Assembly-deficient herpesvirus vaccine
10/26/1999US5972664 Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
10/26/1999US5972658 DNA encoding lung growth factor variant
10/26/1999US5972652 Polynucleotides encoding secreted proteins
10/26/1999US5972651 Polynucleotides and polypeptides of the fifty-four homologue family, (ffh); vectors and transformed host cells; ffh are components of protein secretory apparatus and their inhibition of function is deleterious to bacteria cells
10/26/1999US5972649 Polynucleotide sequence encoding human multiple endocrine neoplasia type 1 protein
10/26/1999US5972648 Hirudin analogs having val1-val2 of naturally-occurring hirudin substituted with ile1-ile2 are preferred for their high antithrombiin activity.
10/26/1999US5972636 ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
10/26/1999US5972625 Assays for inhibitors of leukocyte adhesion
10/26/1999US5972624 Method of identifying ligands which bind recombinant galanin receptor (GALR2)
1 ... 2463 2464 2465 2466 2467 2468 2469 2470 2471 2472 2473 2474 2475 2476 2477 2478 2479 2480 2481 2482 2483 ... 3163